Mary Ann Richie

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri et al. · Journal of Clinical Oncology · 2009 · 416 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +13

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald et al. · Blood · 2013 · 378 citations

Medicine, Oncology, Pharmacotherapy +12

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Nicholas J. Short, Hagop M. Kantarjian, Sanam Loghavi et al. · The Lancet Haematology · 2018 · 118 citations · Full text

Medicine, Hematology, Pharmacology +8

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated <i>FLT3</i>‐ITD Mutated Acute Myeloid Leukemia

Maro Ohanian, Guillermo Garcia‐Manero, Mark J. Levis et al. · American Journal of Hematology · 2018 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

Elias Jabbour, Hagop M. Kantarjian, Jörge E. Cortes et al. · Cancer · 2007 · 113 citations

Medicine, Hematology, Pharmacology +14